跳到正文

#观点/分析

今日 57 条
10月9日周五
  1. BioPharma Dive22

    BioPharma Dive 图表解读:临床试验数据失利与利率上升如何拖累 XBI 生物科技指数回调

    XBI 生物科技指数在8月一度接近每股170美元、较12个月前翻倍后,近几个月横盘回落,Cantor Fitzgerald 与 Raymond James 分析师将其归因于临床试验数据令人失望、利率上升及中期选举不确定性。2026年已有26家私有生物科技公司以至少5000万美元保证收益被收购,超过上市公司的21家,私有公司收购中位价从2023年的4.96亿美元升至10亿美元。

  2. Adam Feuerstein ✡️10

    我读过的最糟糕的AI垃圾$IBRX股票吹票。当然,@DrPatrick还点赞了。

    引用Freedom@ActionFixesFear

    $IBRX $28 billion a year. That was one drug, in one country, doing a single job: rebuilding the immune system that cancer treatment and sepsis burn to the ground. And that was the small version. Today, the whole thing. That drug is ANKTIVA, made by ImmunityBio, and the $28 billion was America alone, built a few weeks ago out in the open, one line of arithmetic at a time. This is post three of four, the series where we put real numbers on what this company could become, from the smallest market on earth to the wildest scenario anyone has floated. And this is the big one. Last February the company put a three-year plan on the record and almost everyone forgot it: more than thirty trials, nine different cancers, gone after one at a time, worldwide. $28 billion was one country and just two of its doors. Today we count the whole board: every cancer in the plan, across the entire planet, in a single pass. Watch what that does. WHERE WE ARE IN THE SERIES Keep the map in front of you, because the whole point of four posts is that each one is bigger than the last. Post one sized the Gulf, the smallest market, and the two immune doors - both of them the same immune collapse, called lymphopenia, one door in cancer patients whose chemo and radiation cause it, the other in sepsis - came back worth a few hundred million to a couple of billion. Post two sized America, the biggest drug market on earth, and those same two doors came back near twenty-eight billion. This third post, the one you are reading now, is the zoom all the way out: every door in the three-year plan, counted for the whole world in a single pass. And the fourth, still to come, is the finale, and it goes all the way: forget revenue entirely - could a drug that rebuilds the immune system turn its maker into the Nvidia of biotech? That one is for next time. For now, back to this post. We stick to the company's three-year plan and count all of it for the whole world at once: the nine cancers, the two immune doors we already sized - lymphopenia and sepsis - and whatever else the plan holds. THE GROUND RULES Before a single number, the same deal as last time, because it is the only reason any of this is worth reading. This is still the careful, fact-checked version. The real price a drug is paid after discounts, not the big headline number. A modest slice of patients, not all of them. The survival benefit still treated as a signal, not a settled fact. And the ground truth under every number below: in America, only one of these nine cancer doors is approved today, bladder, and even there just one narrow form of it, so eight of the nine have no US approval at all. The Gulf has pushed further than the FDA - the UAE and Saudi Arabia have also approved lung, and the UAE a second form of bladder - but that is the whole of it, and nothing anywhere on earth is approved for the two immune doors, lymphopenia or sepsis. On the things we can hold down, we hold them all the way down, exactly as we did in America. The two dials we release are named, and only two: the single country becomes the world, and the two doors become the whole plan. Both of those are just arithmetic we already did in miniature. What stays a bet, out in daylight so you can turn it down yourself, is the same pair from last time, plus one this post is built on: - A survival drug spreads fast - It keeps its price - And the new one: the trials behind the eight unapproved doors actually win We are not inflating anything. We are widening the lens on the exact same careful math, so that when the number gets large, you know exactly how it got there. If it feels like it should be bigger, hold that thought. You are right, and the last post, the one coming next, is where the ceiling lives. THE BOARD HE SHOWED YOU IN FEBRUARY Remember where this plan came from, because it is not ours and it is not new. Back in February, in a detailed press release, ImmunityBio laid the whole thing out: more than thirty active and planned trials across what it calls ten tumor types, gone after one at a time. We size the nine cancers the release names: bladder, lung, glioblastoma, pancreatic, liver, colorectal, triple-negative breast, non-Hodgkin lymphoma and ovarian. Sepsis the company runs as a separate program, so we count it as its own door. And running underneath all of them is the immune collapse this drug is built to reverse, which is lymphopenia. So the board has three kinds of square on it: nine cancers hit head-on, the immune-repair layer under every one of them, and sepsis off to the side. The last post sized one of those squares in one country. This post counts the whole board, for the whole world. THE ENGINE: HOW KEYTRUDA REALLY GOT BIG Here is the piece the last post was missing, and it is the straight answer to a question we raised ourselves. Last time we showed one immune door climb fast to about fifteen billion dollars and then stop, and we told you plainly why it stops: one door has no engine behind it. Keytruda, the best-selling drug in the world, did not reach thirty billion by selling harder into one cancer. It got there by stacking roughly forty approved uses across about twenty cancers, one door opening after another, each new one lifting the pile while the old ones matured. That stacking is the engine. And this post is the engine, because the nine cancers are exactly that pile of doors, each one its own market, each one opening on its own clock. IS A WORLD NUMBER EVEN REAL? So the tempting move, the moment you go global, is to multiply the whole thing at once and print something enormous. The nine doors hold about two million patients a year. But no drug ever reaches every patient who could use it - a doctor has to choose it, an insurer has to pay for it, and it takes years to spread - so only a fraction of them ever actually get it. Call that fraction the share. Say the share is one in five, the kind of level a well-established drug can reach, and it is two million patients, times America's full list price of 322,000 dollars, times one in five, which comes to about 130 billion dollars a year. A number that big is not a real market, it is make-believe. No set of health systems on earth writes a check like that for one drug, and nobody outside America pays the full American price. So we throw it out, the same way we threw out the 39 billion in the last post, and for the same two reasons: the price is wrong, and the reach is wrong. Fix both and the number that is left is one you can actually defend. Here is how we build it. COUNT THE DOORS Count them the way we count everything, one simple sum per door: how many patients a year that cancer puts on the table across the whole world, times a tenth of them actually reached, times a real price of about 120,000 dollars, the blended net actually paid across the wealthy world after discounts: lower than what a survival drug like Keytruda is estimated to collect in America, higher than what Europe and the Gulf pay. One note before the list, because it governs every line of it: the patient counts are the whole world's, but that 120,000-dollar price only holds in the wealthy countries where the drug is approved, so read the tenth we reach as mostly those places, America, Europe and the Gulf. The poorer world is real numbers of patients at a far lower price, and we add it in by name further down rather than pretend one price fits the planet. And the patient pool in each line is itself a sum: the whole world's cases of that cancer, times the slice of them in the late, advanced stage the trial is actually aimed at. So here is every door with the full math, the world's cases times that slice to get the patients, then those patients times a tenth reached times the 120,000-dollar price: 1. Lung, after the checkpoint drugs stop working: 2,480,000 cases a year worldwide x 17% in that late stage = about 420,000 patients; then x 10% reached x $120,000 = about $5.0 billion 2. Colorectal, the common kind that does not respond to immunotherapy, later line: 1,930,000 x 20% = about 385,000 patients; x 10% x $120,000 = about $4.6 billion 3. Liver, advanced: 866,000 x 40% = about 346,000 patients; x 10% x $120,000 = about $4.2 billion 4. Pancreatic, advanced: 511,000 x 50% = about 256,000 patients; x 10% x $120,000 = about $3.1 billion 5. Non-Hodgkin lymphoma, relapsed: 553,000 x 30% = about 166,000 patients; x 10% x $120,000 = about $2.0 billion 6. Glioblastoma, the deadliest brain cancer: about 150,000 cases a year worldwide, nearly all of them in that late stage = about 150,000 patients; x 10% x $120,000 = about $1.8 billion 7. Ovarian, platinum-resistant: 325,000 x 40% = about 130,000 patients; x 10% x $120,000 = about $1.6 billion. 8. Triple-negative breast, advanced or high-risk: 2,300,000 breast cases x 12% triple-negative x about 55% advanced or high-risk = about 150,000 patients; x 10% x $120,000 = about $1.8 billion 9. Bladder, the only one approved in the US today: 615,000 x 15% (the high-risk early form it treats) = about 92,000 patients; x 10% x $120,000 = about $1.1 billion Add the nine and you are looking at roughly two million patients a year, and at a tenth of them reached, about twenty-five billion dollars a year from direct cancer treatment alone. Turn that single dial from a tenth to a fifth, the kind of share a drug reaches once it is established, and it is about fifty billion, but treat that fifty as the ceiling of this dial, not a clean doubling, because reaching a fifth of the world means either filling up the wealthy markets or pushing into the poorer ones where the price falls, and both pull the real figure back toward the twenty-five. And say the rest clearly, because it is the whole point of this section: eight of those nine doors have no US approval. They are still in trials or on paper. This is the size of the board if the trials win, not a promise that they do. One door is real today. The other eight are the bet. NOW WATCH THE BOARD FILL IN The final, full-size number is not how this arrives, any more than it was in America. It arrives as a climb, and the climb here has a shape the last post could not show, because this time the growth is doors opening, not one door deepening. So read the clock the same careful way: each door starts counting from the day it is approved, not from today, and the approvals have not happened and may never. What follows is the shape of the stack filling in, not a dated promise. - At the start, one door is open: bladder, the only approval that exists, ramping toward its billion as it reaches its patients - In the first years, the lead engine opens, lung, the furthest along of the new doors, and the immune-repair layer switches on beneath it. A few doors, early in their own climbs: the first several billion a year - Around the middle of the decade, with perhaps half the board open and the lead doors nearing a tenth of their patients, the pile is already in the low tens of billions - Out near ten years, the whole board mature, every cancer door open and the immune repair folded in, the cancer side of the plan lands at its full size, which we will size in a moment That is the engine running: not one curve bending toward a ceiling, but door after door opening and stacking, the exact mechanism that carried Keytruda from one cancer to thirty billion dollars. It is also why this is slower than it is dramatic. Brand-new spending like this is the hardest kind for a health system to take on, so the money arrives in stages, a fresh slice of budget at a time, no matter how badly the patients want it. NOW STACK THE IMMUNE LAYER, BUT DO NOT DOUBLE-COUNT Under all nine of those cancers runs the immune door we already sized: lymphopenia, the collapse of the body's standing army that chemo and radiation cause. In America alone that door matured near fifteen billion dollars. Open it across the rest of the approved world and the pattern is simple to name, so that nobody disappears the way they did before. - America is the single biggest slice, near fifteen billion - Europe adds eight to ten billion. The drug already holds a conditional approval there, but for bladder cancer only, not the immune doors; the number of patients is close to America's, but the real prices paid run lower - The rest of the wealthy world, with the Gulf where ImmunityBio already sells, adds perhaps five to eight billion more - The entire poorer world, from Brazil to Russia to India to China to Africa, adds a lot of patients but very little money, because there the price has to collapse to a funder level, paid by an outside health fund, before anyone can be treated at all. That is the honest shape of it. The fifty to ninety billion is the rich, approved, paying world. The rest of the planet is where most of the world's patients actually live, the two biggest countries on earth, China and India, among them. But it is not approved, it cannot pay Western prices, and counting it would mean guessing at a huge number we cannot stand behind. So we bank none of it. If prices or funding ever rise out there, that is upside on top of the number, not inside it. But here is the discipline that keeps the math clean, and it is the easiest number in the whole series to get wrong. A lung patient we just counted in the cancer layer is often the very same lung patient whose immune count we would repair in the immune layer. One patient is one patient. So we do not stack those two layers on top of each other and pretend they are different people. We count each patient once. The cancer layer and the cancer side of the immune layer are two names for treating mostly the same people, paid for out of one budget, and we count that group a single time. What the immune layer genuinely adds on top is the patients the nine doors miss: the other cancers on chemo and radiation that are not on our board at all. That slice is real, and it is new, and it is the only part of the immune layer we let add to the total. THE ONE DOOR THAT IS GENUINELY SEPARATE Sepsis is the exception, because septic patients are a different population from cancer patients, so this door stacks cleanly on top without any double-counting. It is also, exactly as in the last post, the widest and least certain dial we hold. No drug has ever been proven to reverse the immune collapse of sepsis; its trial has barely started, the earliest-stage of any door on this board; and sepsis is the graveyard where one promising drug after another has died. Soon-Shiong makes the bullish case that it could move fast, and with a need this vast and immediate it might. But because nothing has ever worked here before, we size it with the most caution of all: the number of sepsis patients worldwide is far larger than cancer, yet that failure history and the long road to approval hold back what anyone can realistically reach, so we assume it opens years behind the cancer doors and climbs the slowest. As for the number: in America alone, last time, this door came to about thirteen billion dollars, roughly 850,000 Americans a year who go septic and lose their immune defences, times a quarter of them reached, times about 60,000 dollars a course, half the cancer price. The rest of the approved world, Europe and the other wealthy countries and the Gulf, sees at least as much sepsis again, though it pays less per patient, so it adds more on top; and the poorer world, where most sepsis on earth actually happens, piles on patients but almost no money, because there the price collapses. Add it up and hold the band wide, because this is the least certain door of all: somewhere around twenty to thirty-five billion dollars for the whole approved world once it is fully grown, and it is the first to turn down if you doubt it. THE WHOLE BOARD So put the board together, with the overlap netted out. Start with the nine cancers treated directly: twenty-five billion dollars at a tenth of their patients, up to fifty at a fifth. Then the immune-repair layer, lymphopenia, which we just sized at around thirty billion across the world. But almost all of those are the very same patients, the lung and colorectal and liver cases we already counted in the direct layer, so we cannot add that thirty billion on top. We count each patient once. What is left over, the only genuinely new money, is the immune repair in the cancers that are not among our nine, a smaller slice worth perhaps five billion. Add that to the direct layer, twenty-five to fifty plus about five, and the cancer universe lands somewhere around thirty to fifty-five billion dollars a year once it is fully grown. Sepsis, genuinely separate, adds another twenty to thirty-five. Together, the whole plan is roughly fifty to ninety billion dollars a year, if the trials win and the approvals come, across the whole approved world. Read that range the right way: fifty is where it realistically lands if the doors open to about a tenth of their patients, and ninety is the top, the figure you reach only if nearly every door wins and holds its price. The floor is the expectation. The ceiling is the dream. That is the number the last post was a corner of. It is the scale of a Keytruda and more, reached the way Keytruda actually reached it, by stacking door after door. And it is built at a tenth of the patients, the real discounted prices, and eight of nine cancer doors still unproven. The entire poorer world is left out of the count, China and India among it, its billions sitting on top of this number, not inside it. Every dial still turned down, except the two we told you we were releasing. That is what fifty to ninety billion looks like with the brakes still on. WHO DOES IT TAKE THE MONEY FROM? The first question about a number this big is always who it takes the money from, and across the whole world the answer is still the one from America: almost nobody, because it replaces almost nothing. Chemotherapy and radiation are used exactly as they are today; ANKTIVA is the layer that repairs the immune damage they cause, not a substitute for them. There is no lymphopenia drug to replace, and even in the nine cancers it works mostly after the checkpoint drugs stop, alongside them, not in their place. So this is new spending, in a category that does not yet exist, the way immunotherapy grew the whole cancer market instead of splitting up the old one. That one fact cuts both ways, and both matter: it is why the prize takes from no one and the ceiling is so high, and it is why the climb takes a decade instead of a jump, because brand-new spending is the hardest kind for a system to find room for. THE SQUARE WE LEFT BLANK ON PURPOSE There is one more square on this board, and we are deliberately not putting a number on it, because it is too early and because it would swallow everything else if we did. Every number above is about treating cancer once it exists. The plan has an arm aimed at stopping cancer before it ever forms, in people whose genes almost guarantee it. This is the cancer-prevention vaccine you may have seen Soon-Shiong talking about: a vaccine that trains the immune system to recognise and clear the very first cancer cells, with ANKTIVA added to keep that immune army switched on. The first test is in Lynch syndrome, an inherited defect that carries a fifty to eighty percent lifetime cancer risk, in a trial run by the National Cancer Institute that is due to read out around next year. If treating cancer is a large market, preventing it is a far larger one, because the customer is not the sick, it is everyone at risk. We flag it so you know the board has a square we left intentionally blank. We are not going to pretend to size a market that does not exist yet. NONE OF IT IS SIGNED Say the hard part plainly, the same way we have every time. Nothing here is approved for lymphopenia or for sepsis anywhere on earth, and eight of the nine cancers have no US approval either. Every figure above is the size of a prize that opens only if and when the trials win and the regulators agree, and when you read a share of patients, the clock on it starts at an approval that has not happened and may never. - The patient counts are real and sourced - The price is a number we chose and labeled - The share is a dial, and it is in your hand - The survival benefit is a real but unproven signal, not a fact - The receipts, every figure and its source, are in the reply below None of this is advice. THE NUMBER, AND HOW WRONG IT COULD BE So here is the whole board, for the whole world, in one line: a plan that, if its trials win and its doors open the way Keytruda's did, climbs over about a decade toward fifty to ninety billion dollars a year, at the real discounted prices, a tenth to a fifth of the patients, the poorer world uncounted, eight of nine cancer doors still unproven. That would be the scale of the biggest drug franchises on earth, reached the careful way, one door at a time. And could the real number land far from this? Of course it could, further than in any post before it, because this one stacks the most bets. Every input is a judgment that could prove too high or too low: how many patients each case really holds, how many doors actually win, how fast the world pays for new medicine, what an insurer really hands over once the discounts come off. We built it as carefully as we know how and showed every step, because the point was never to hand you one number to trust. It was to hand you the dials. Believe the drug is stronger than we assumed, turn them up. Think we are dreaming, turn them down. The number moves with you, and we held every one of them below its ceiling the entire way. WHAT COMES NEXT $50-90 billion a year. That is the whole board, for the whole world, and we held it inside the rules the entire way: real prices, real adoption, real medicine, the same careful math we ran in one country, widened to all of them. Still playing by the rules of what a drug is allowed to earn. Which leaves exactly one question, the one almost nobody says out loud. What happens to a company if a drug like this does not play by those rules at all? What if it does not just earn like a big drug, but breaks out the way Nvidia broke out in AI, and becomes the foundation the whole world builds its immunotherapy on? What is a company like that worth then? That is the finale, coming next. We kept every number inside the rules today; next time we find out what is on the other side of them. And the number, as you can probably guess, will be a little different from this one. Stay tuned.

  3. BMJ10

    在研究中支持公平、多样性与包容性

    研究中对公平、多样性、包容性和可及性(EDIA)考量的缺失,正威胁医疗健康研究的科学性与伦理完整性。代表性不足代价高昂且不公正,无意中排除最可能从试验证据中获益的患者是改进重点,黑人受试者被排除在癌症试验之外即为重要例证。孕妇或认知障碍者被有意排除,以及忽视结构性歧视(如脉搏血氧仪在深色皮肤上高估血氧)导致错误结论,正成为新兴关注领域。

  4. MedCity News12

    制药商业团队能从数字健康学到什么:AI 时代下的商业化重构

    制药商业团队在AI投资上多聚焦于更快的话术规划、报告与内容审批,而非重新定义商业职能的可能性。数字健康公司以精简、整合的商业团队围绕少数明确结果构建,能在数周内交付功能,而制药商业团队仅收集需求就可能耗费一个季度。作者建议制药业借鉴数字健康模式,用共享数据层替代各自为政的仪表盘,并以跨职能的AI认知指挥中心取代顺序审批链。

  5. Adam Feuerstein ✡️0

    我是个烂人。真的。

    引用Kimchi_Trades@kimchi_trades

    $VKTX trading up a bit today on a bounce, with the coincidence of @adamfeuerstein out running his mouth on it this AM. Its generally accepted that he's a manipulator-for-hire in the biotech world. So something cooking it seems

  6. 梅斯医学 MedSci18

    罗马Ⅴ标准解读与中国实践思考:儿童功能性消化不良的诊疗建议

    2026年罗马Ⅴ肠-脑互动异常诊断标准正式发布,对儿童功能性消化不良(FD)的诊断频率、亚型定义及治疗策略作出重要更新。文章在解读该标准核心更新的基础上,整合国内最新研究证据与专家共识,提出适合中国儿科临床实践的诊疗建议。国内已先后发布2022年《婴幼儿功能性消化不良综合征诊断共识》及2025—2026年《儿童功能性消化不良中西医结合诊疗指南》等文件。

  7. 梅斯医学 MedSci22

    《AHA/ACC/ESC/WHF第二版心力衰竭通用定义专家共识(2026)》解读

    《AHA/ACC/ESC/WHF第二版心力衰竭通用定义专家共识(2026)》解读文章介绍了该共识的重要更新,并给出各类定义的中文翻译推荐。新共识将基于LVEF的心力衰竭分类更新为HFrEF(LVEF<50%)、HFpEF(LVEF≥50%)和HFimpEF,并提出改善型、缓解型和康复型心力衰竭三个治疗转归阶段定义。

  8. BMJ5

    作者回应 Seamark 和 Tucker:社区医院资源缩减与区域差异问题

    作者回应 Seamark 和 Tucker 关于社区医院价值的观点,认同其可作为不再需要综合医院全套设施但需持续住院康复、评估或治疗患者的宝贵资源。但全国中间照护审计等数据显示,此类医院数量正在缩减,且因地方历史而非刻意决策导致区域分布差异显著,部分地区有多家而城市地区可能一家都没有。社区医院同样面临"出口阻塞",患者因等待社会照护或居家社区健康服务而无法出院。

  9. 梅斯医学 MedSci22

    围术期自主神经系统失衡如何影响手术结果:一项系统性综述

    杨建军教授与马大青教授在《British Journal of Anaesthesia》发表系统性综述,阐述围术期交感神经过度激活与副交感张力降低驱动全身应激反应、免疫抑制及多器官功能障碍,并评估右美托咪定等药物与非药物干预对自主神经再平衡的疗效。综述还指出低HRV与术后神经认知障碍相关,术后自主神经失衡可能增加感染、癌症复发与转移风险。

  10. Pharmaphorum12

    如何打造 AI 原生的 CRO

    临床研究行业正从"把 AI 塞进现有流程"转向围绕 AI 重新设计工作流,即成为 AI 原生的 CRO。AI 可依据方案和申办方偏好自动生成符合 CDASH 标准的 CRF 并完成变量映射,数据从首条记录起即标准化并直通 SDTM、ADaM,将数周协调压缩为一次审阅。相关数据审阅平台已在多项生产研究中运行,审阅速度明显快于传统流程,并具备独立于编程路径的统计 QC。

  11. 梅斯医学 MedSci22

    特应性皮炎在备孕、妊娠与哺乳期系统性抗炎治疗北欧专家共识指南解读

    北欧专家共识针对特应性皮炎(AD)在备孕、妊娠与哺乳期的系统性抗炎治疗给出指导意见,指出围孕期系统治疗存在明显证据缺口:缺乏大样本胎儿安全性数据,现有研究多聚焦女性生育能力,对父系用药致畸风险关注甚少。共识从孕前、孕期、哺乳期治疗及多学科协作等方面进行解读。

  12. STAT News10

    研究Roe案被推翻后堕胎可及性变化,Pleasants用Reddit数据与NLP追踪新障碍

    UC Berkeley公共卫生学院研究生Betsy Pleasants在2022年Roe v. Wade被推翻后,将博士论文转向研究Reddit论坛r/abortion的数千条帖子,结合自然语言处理(NLP)与定性细读,实时追踪堕胎可及性障碍。研究除印证高费用、预约紧张等已知障碍外,还发现邮寄堕胎药物延迟、在线订购平台可信度低及对寻求堕胎法律风险的担忧等较少被关注的挑战。

  13. STAT News12

    观点:50年前我与同事开展的基础研究,如何催生IL-2与HIV发现

    50年前,我与同事发表论文描述了IL-2(白细胞介素-2),这一发现使人类T细胞得以在体外持续培养,进而促成首个人类逆转录病毒HTLV-1及HIV的发现,并证明HIV是AIDS的病因。IL-2还推动了现代细胞免疫学与肿瘤免疫治疗的发展。作者强调,基础研究的最重大价值往往无法在立项时预知,不应只资助应用前景明确的项目。

  14. STAT News15

    观点:美国人口普查拟议变更或对公共卫生造成灾难性影响

    美国联邦公报9月10日发布公告,拟对2030年十年一次人口普查实施三项未经测试的重大变更:将统计范围限制为公民或合法永久居民、改变常住地认定规则、禁止询问种族和族裔及性取向问题。作者指出,这些变更将缩小分母、推高发病率和死亡率统计数字,并破坏联邦资金分配、人口调查抽样框架及医院规划、应急服务等50项普查数据用途。

  15. STAT News20

    STAT+:MAHA 运动能否挺过中期选举?

    美国卫生部长 Robert F. Kennedy Jr. 发起的 MAHA 运动在中期选举竞选活动中几乎销声匿迹,难以在关键选战中建立资金与信息传播立足点。尽管 Kennedy 对美国食品供应和企业影响力的批评仍具广泛吸引力,MAHA 尚未将这些议题转化为有政治分量的具体政策或事业。部分支持者认为,11 月 3 日投票将决定 MAHA 的存亡。

  16. 梅斯医学 MedSci22

    《2025年乳腺感染性与炎症性病变管理指南》解读——来自美国乳腺外科医师学会、乳腺影像学会和美国病理学家学会

    美国乳腺外科医师协会(ASBrS)、乳腺影像学会(SBI)及美国病理学家学会(CAP)联合发布《2025年乳腺感染性与炎症性病变管理指南》,聚焦哺乳期乳腺炎(LM)、肉芽肿性乳腺炎(GM)及导管周围乳腺炎伴鳞状上皮化生(PDM-SMOLD)三类病变,提出以尽量减少有创干预为核心的诊疗路径。本文解读该指南重点内容,并与国内《乳腺炎症性疾病诊治临床实践指南(2025版)》对比分析。

  17. 梅斯医学 MedSci62

    2026 ADA/EASD共识更新2型糖尿病管理:从降糖转向整体风险管理

    美国糖尿病学会(ADA)与欧洲糖尿病研究协会(EASD)发布2026版2型糖尿病管理共识,对2022年版进行更新,将重点从高血糖管理扩大到2型糖尿病及其相关多种长期疾病风险的整体管理。

    推荐理由:共识把2型糖尿病管理从降糖扩展到整体风险管理,并给出SGLT2抑制剂与GLP-1的早期使用建议。

  18. 梅斯医学 MedSci22

    类风湿关节炎(蒙冲静)苗医药诊疗方案专家共识发布

    贵州省中医药学会风湿病专业委员会组织28位苗医药学及中医风湿病专家,编写发布《类风湿关节炎(蒙冲静)苗医药诊疗方案专家共识》。该共识整合苗医学"毒、亏、瘀"理论与类风湿关节炎现代病理机制,构建苗医特色疗效评价体系,涵盖苗医术语、诊断要点、证候分型、治疗方案、护理调摄和疗效评价等内容,旨在填补苗医药治疗类风湿关节炎领域空白,推动民族医药诊治规范化与标准化。

  19. 梅斯医学 MedSci22

    王共强:帕金森病临床前驱期症状与风险分层

    帕金森病前驱期可持续3~20年,特发性快速眼动睡眠行为障碍(iRBD)是预测价值最高的单一临床标志,2~5年转化风险约15%~35%,12~25年可达91.9%。α-突触核蛋白种子扩增技术(SAA)与多模态影像联合应用,前驱期诊断准确率可达92%。MDS前驱期研究标准以贝叶斯概率进行风险分层,后验概率≥80%为很可能前驱期,适用于神经保护试验富集入组。

  20. 梅斯医学 MedSci22

    PROBAST+AI:基于传统或人工智能方法的预测模型研究质量、偏倚风险及适用性评价工具解读

    PROBAST+AI 于2025年更新,在原有 PROBAST 框架上扩展,以应对基于 AI/ML 算法开发或评估临床预测模型时特有的方法学挑战。该工具从研究对象与数据源、预测因子、结局、分析4个领域评价模型开发质量与评估偏倚风险,分别涵盖16、18个信号问题;并从研究对象与数据源、预测因子、结局3个领域评价适用性。

  21. Prof Peter Hotez MD PhD DSc(hon)8

    我写的关于脊髓灰质炎早期历史的书,包括@asabinbio撰写的阿尔伯特·萨宾新传记,令人遗憾的是脊髓灰质炎可能重返美国。由于疫苗接种率急剧下降,麻疹已经重返美国,我预测明年我们可能开始看到先天性风疹病例,百日咳也卷土重来。希望这不会扩展到脊髓灰质炎,但几年前它曾出现在纽约的废水中,所以并非不可能。

  22. 梅斯医学 MedSci20

    美国牙科协会急性牙痛药物治疗循证临床实践指南(2023—2024)解读及对我国的临床启示

    美国牙科协会于2023、2024年相继发布儿童、青少年、成人及老年人急性牙痛药物治疗循证临床实践指南,确立"非甾体抗炎药优先、严格限制阿片类药物、分年龄段精细化管理"的新体系。本文系统解读该指南的循证基础及分年龄段用药方案,并结合我国诊疗规范、专家共识及国家基本药物目录,从药物可及性、处方习惯、政策衔接、基层医疗资源配置等角度探讨本土化实施路径,提出符合我国国情的全年龄段分层用药方案。

  23. 梅斯医学 MedSci18

    产前全外显子组测序变异解读中临床意义不明变异的挑战

    产前全外显子组测序(WES)在高危胎儿中显著提升单基因病检出率,但也带来较高比例的临床意义不明变异(VUS),造成决策压力、表型局限及报告标准不统一等困境。文章结合国内外指南,从检测前、检测中及检测后提出规范化管理策略,包括优化知情同意、多维证据整合、强化多学科协作及动态重分析机制。

  24. The Lancet12

    PISA 2025 结果揭示 AI 时代健康素养危机

    PISA 2025 评估显示,来自 91 个国家和经济体的逾 76 万名 15 岁学生在阅读、数学和科学方面的表现出现令人担忧的恶化。PISA 虽不直接测量健康素养,但其所评估的认知能力日益成为人们理解健康信息的基础,这一结果应引起健康领域关注。

  25. The Lancet22

    呼吁立即监管医疗AI的前瞻性开发

    《The Lancet》通讯文章指出,AI在医学领域的推进速度已超出监管、伦理与专业反思的跟进能力。作者认为,当前"只要能开发就应开发、临床定位事后讨论"的默认逻辑应当被逆转,呼吁立即对医疗AI的前瞻性开发加以监管。

  26. The Lancet5

    《柳叶刀》评论:和平的医学

    《柳叶刀》发表评论文章,借霍布斯《利维坦》中“孤独、贫穷、肮脏、野蛮而短暂”的人生论断切入,指出得益于卫生体系的发展与扩张,这一状况对许多人而言已不再成立,但显然并非所有人。文章进而引出霍布斯关于人类本性的更广泛观点:若社会缺乏“共同权力”的统治,人的自然倾向便是“一切人反对一切人的战争”。

  27. The Lancet22

    《The Lancet》评论:缩小HIV青少年患者的死亡差距

    尽管抗逆转录病毒治疗(ART)取得重大进展,HIV青少年患者与普通人群之间仍存在显著死亡差距,其ART覆盖率约60%,低于整体78%的水平。Mutsa Bwakura-Dangarembizi等人在《The Lancet》报告的LATA试验,在集中了全球157万HIV青少年中大多数的四个非洲国家开展,提示长效注射治疗方案有望缓解青少年每日口服ART的依从性难题。